EN | UA
EN | UA

Help Support

Back

Can nicotine mitigate dysregulated inflammatory responses in coronavirus disease?

COVID-19 COVID-19
COVID-19 COVID-19

What's new?

Alpha 7 nicotinic cholinergic receptor agonists, like nicotine and GTS-21, might have a protective role against severe symptoms of COVID-19 infection.

A study published in "The Journal of Immunotoxicology" indicated that nicotine or GTS-21 (low molecular weight compounds that lead to activation of cholinergic anti-inflammatory reflex) might represent a promising approach for attenuating dysregulated inflammation in people suffering from severe COVID-19.

Myalgia, coughing, acute inflammatory lung injury, shortness of breath, and fever are the commonly reported mild-to-moderate symptoms in COVID-19 people. On the other hand, respiratory failure and acute respiratory distress syndrome (ARDS) occur in people with severe COVID-19. To some extent, the cytokine-storm syndrome (a dysregulated hyperinflammatory response due to elevated levels of circulating cytokines) mediates ARDS.

There are FDA-approved agents (like dexamethasone or other corticosteroids and interleukin-6 inhibitors, including siltuximab, tocilizumab, and sarilumab) that alleviate dysregulated inflammatory responses occurring in coronavirus-infected people, But, the effectiveness of these therapies have demonstrated inconsistency.

By minimizing extracellular levels of high mobility group box-1 (HMGB1) in circulation and airways, compounds that lead to activation of vagus nerve-mediated cholinergic anti-inflammatory reflex (like GTS-21) reduce inflammatory lung injury/ARDS.

HMGB1 might be a crucial mediator of "cytokine-storm syndrome." In coronavirus-infected individuals, raised plasma levels of HMGB1 have been noted. A substantial negative correlation exists between clinical outcomes and plasma levels of HMGB1. Nicotine is capable of activating the cholinergic anti-inflammatory reflex, that mitigates the up-regulation and excessive production of pro-inflammatory cytokines/chemokines. This, in turn, attenuates inflammatory lung injury elicited by SARS-CoV-2 infection.

Source:

The Journal of Immunotoxicology

Article:

From nicotine to the cholinergic anti-inflammatory reflex - Can nicotine alleviate the dysregulated inflammation in COVID-19?

Authors:

Alex G Gauthier et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: